GlassScriptPhysician profile
Omar Alsamman
NPI 1457319808
$3,116.50
in general payments reported to CMS, 2019-2025
19 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $137 · 2021: $211 · 2022: $719 · 2023: $545 · 2024: $428 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198 · Travel and Lodging: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.65 |
| Travel and Lodging | $146.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,251.80 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $412.46 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $267.57 | 2019 | |
| Amarin Pharma, INC. | $183.56 | 2019-2022 | |
| Abbvie INC. | $169.72 | 2022-2024 | Ubrelvy |
| Cook Medical LLC | $146.97 | 2023 | Hemospray |
| Otsuka America Pharmaceutical, INC. | $124.25 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $82.26 | 2021-2023 | Eliquis |
| Amgen INC. | $78.75 | 2022-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $73.03 | 2021-2023 | |
| Lilly USA, LLC | $69.65 | 2022-2023 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $69.09 | 2019-2020 | |
| Glaxosmithkline, LLC. | $46.17 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $39.47 | 2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $26.55 | 2025 | Heplisav-B |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $21.93 | 2025 | Doc Band |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.59 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Alsamman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.